

Curriculum vitae

Name	Andreas Kerschbaumer
Address	Medical University of Vienna, Department of Medicine III, Division of Rheumatology Währinger Gürtel 18-20, 1090, Vienna, Austria
E-Mail	andreas.kerschbaumer@meduniwien.ac.at
Citizenship	Austria
ORCID	0000-0002-6685-8873
Link	https://www.ncbi.nlm.nih.gov/myncbi/andreas.kerschbaumer.1/bibliography/public

Education

04/2025	Venia docendi, Medical University of Vienna Habilitation thesis: <i>"Strategies for Interpreting and Optimizing Treatment Outcomes in Rheumatoid and Psoriatic Arthritis Clinical Trials"</i>
03/2018 – 10/2024	Residency and fellowship in internal medicine & rheumatology (ÄAO2015)
10/2016 – 09/2023	Doctoral/PhD program (N094), Medical University of Vienna PhD Thesis: <i>"Discovering Influencing Factors on Efficacy Outcomes in Inflammatory Arthritis Clinical Trials"</i>
10/2010 – 10/2016	Study of medicine (N202), Medical University of Vienna MD Thesis: <i>"Serum Complement C3 as a Possible Disease Activity Marker in Psoriatic Arthritis"</i>

Work experience

05/2025 – today	Postdoctoral scholar Stanford University, Division of Immunology and Rheumatology
10/2024 – 04/2025	Attending physician in rheumatology (research leave starting 5/2025) <i>Medical University of Vienna, Department of Medicine III, Division of Rheumatology.</i>
03/2018 – 09/2024	Residency: Internal medicine, Fellowship: internal medicine & rheumatology (ÄAO2015) <i>Medical University of Vienna, Department of Medicine III, Division of Rheumatology</i>
10/2016 – 02/2018	Research / PhD studies (full time employment) <i>Medical University of Vienna, Department of Medicine III, Rheumatology</i> Clinical research (outcomes research, data science, systematic literature reviews, meta-analyses), database development, sub-investigator in clinical trials

Taskforces / Memberships (selection)

06/25 – today	EULAR Quality of Care committee member
03/24 – today	EULAR Recommended Methodologist in Training
11/24 – today	EULAR recommendations for the management of RA with synthetic and biological DMARDs: 2025 update – Co-Methodologist
06/23 – 11/24	Consensus statement: Points to consider for the treatment of immune mediated inflammatory diseases with JAKi: 2024 Update – Methodologist
11/22 – 03/24	EULAR Taskforce: EULAR Recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 Update – Fellow
2018 – 2023	The Rheumatology Education Group (TREG) – International faculty
2021 – 2022	EULAR recommendations for the management of RA with synthetic and biological DMARDs: 2022 update – Fellow
2020 – 2022	Taskforce on the consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions – Co-Methodologist
2019 – 2021	EULAR Taskforce: Points to Consider for Conducting Clinical Trials in Individuals at risk of Rheumatoid Arthritis – Co-Methodologist
2018 – 2019	Consensus statement: Points to consider for the treatment of immune mediated inflammatory diseases with Janus kinase inhibitors – Fellow
2018 – 2019	EULAR Taskforce: EULAR Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies: 2019 Update – Fellow
2018 – 2019	EULAR Taskforce: EULAR recommendations for the management of RA with synthetic and biological DMARDs: 2019 update – Fellow

Awards

Emerging Investigator Excellence Award (ACR convergence 2024)

Thesis awards (vFWF & Austrian rheumatologic society 2023)

Publication awards (Austrian rheumatologic society 2016 & 2022 & 2023)

1st place of the Theodor-Billroth-Price (Austrian Doctors Chamber of Vienna 2021)

Researcher of the month January 2021 (Medical University of Vienna 2021)

Peer reviewing activity

Annals of the Rheumatic Diseases | JAMA Internal Medicine | Joint Bones and Spine | Lancet | Lancet Rheumatology | Rheumatology (Oxford) | Seminars in Arthritis and Rheumatism

Research interests

Clinical trial design in rheumatoid arthritis and psoriatic arthritis and identification of factors influencing outcomes using novel statistical and machine learning methods. Developing strategies for clinical and immunological phenotyping of rheumatoid arthritis.

Publications (selection)

Kerschbaumer A, Steiner M, Pruckner P, Wildner B, Maad M, Smolen JS, Aletaha D. Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis. **Ann Rheum Dis**. 2025 Aug 1:S0003-4967(25)04243-8. doi: 10.1016/j.ard.2025.07.010.

Kerschbaumer A, Steiner M, Khalili S, Shehab A, Jordanov A, Wildner B, Maad M, Smolen JS, Aletaha D. Global Recruiting Patterns Affect Placebo Response Rates In Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis. **Arthritis Rheumatol**. 2025 Jun 30. doi: 10.1002/art.43302.

Kerschbaumer A, Smolen JS, Ferreira RJO, et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. **Ann Rheum Dis**. Published Online First: 19 March 2024. doi: 10.1136/ard-2024-225534

Kerschbaumer A, Stimakovits NM, Smolen JS, Stefanova T, Chwala E, Aletaha D. Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis. **Ann Rheum Dis**. 2023 Jan 10:ard-2022-223349. doi: 10.1136/ard-2022-223349. PMID: 36627167.

Kerschbaumer A, Sepriano A, Bergstra SA, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. **Ann Rheum Dis**. 2022 Nov 11:ard-2022-223365. doi: 10.1136/ard-2022-223365.

Kerschbaumer A, Rivai ZI, Smolen JS, et al. Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis. **Ann Rheum Dis**. 2022 Jun 20;annrheumdis-2021-221807. doi: 10.1136/annrheumdis-2021-221807.

Kerschbaumer A, Smolen JS, Herkner H, et al. Efficacy Outcomes in Phase 2 and Phase 3 Randomized Controlled Trials in Rheumatology. **Nature Medicine**. 2020 Apr 20. doi: 10.1038/s41591-020-0833-4.

Kerschbaumer A, Aletaha D. Targeting p19 in Psoriatic Arthritis: More Than Just Another Therapeutic Approach? **Lancet**. 2020 Apr 4;395(10230):1091-1093. doi: 10.1016/S0140-6736(20)30525-0 (Letter).

Aletaha D, **Kerschbaumer A**, Smolen JS. Tofacitinib for Psoriatic Arthritis. **New England Journal of Medicine**. 2018 Feb 22;378(8):775. doi: 10.1056/NEJMc1715189 (Letter).